A Network Pharmacology Study Based on the Mechanism of Citri Reticulatae Pericarpium-Pinelliae Rhizoma in the Treatment of Gastric Cancer

Abstract

Objective. To explore the mechanism of action of Citri Reticulatae Pericarpium-Pinelliae Rhizoma (CRP-PR) in treating gastric cancer (GC) by using pharmacology network. Methods. Based on oral bioavailability and drug-likeness, the main active components of CRP-PR were screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). DisGeNET Database was used to establish target databases for GC. Cytoscape software was used to construct a visual interactive network diagram of “Active Component-Target” and screen out the key targets. The STRING database was used to construct a protein interaction network. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the key targets. Additionally, TCGA and HPA databases were used for key target verification. Results. Thirty-seven active components of CRP-PR were screened. The results of network analysis showed that the main components include 8-octadecenoic acid, stigmasterol, ferulic acid, and naringenin of the CRP-PR herb pair. The key targets of the PPI network mainly involved GAPDH, MAPK3, JUN, STAT3, GSK3B, SIRT1, ERBB2, and SMAD2. GO enrichment analysis involves 540 biological processes, 118 cellular components, and 171 molecular functions. CRP-PR components were predicted to exert their therapeutic effect on the tumor signaling pathway, PI3K-Akt signaling pathway, MAPK signaling pathway, and estrogen signaling pathway. The validation of the key genes in the TCGA and HPA database showed that most of the key target verification results were consistent with this article. Conclusion. CRP-PR can treat GC by mediating PI3K-Akt signal pathway, MAPK signal pathway, and other biological processes such as tumor cell proliferation, apoptosis, and vascular regeneration, which embodies the synergistic effect of multi-components, multi-targets, and multi-channels, and provides the theoretical basis and research ideas for further study of CRP-PR in treating GC. 8-octadecenoic acid, stigmasterol, ferulic acid, and naringenin may be the material basis for the treatment of GC.

Network pharmacology and experimental verification based research into the effect and mechanism of Aucklandiae Radix–Amomi Fructus against gastric cancer

“…MAPK3 is a member of the MAPK family. MAPK is an important signal transmitter in cells that can participate in a variety of biological processes, such as cell proliferation, differentiation, and immune defense, by phosphorylating nuclear transcription factors and related enzymes 58 . IL6 is a pleomorphic cytokine involved in various biological processes, such as inflammation and tumor development 59 , 60 .…”

Exploring the mechanism of andrographolide in the treatment of gastric cancer through network pharmacology and molecular docking

“…It has been reported that andrographolide has anti-angiogenic activity which is mediated through preventing VEGFA-induced phosphorylation and activation of VEGFR2 and MAPKs 53 . Transcription factor JUN is a risk gene for GC, and it can promote the occurrence and development of GC by participating in the regulation of the MAPK signaling pathway 54 . Andrographolide that involved inhibiting Hsp90 function and downregulating Hsp90 client proteins, broadening the molecular basis of andrographolide-mediated anticancer effects 55 .…”

Integrated comparative metabolomics and network pharmacology approach to uncover the key active ingredients of Polygonati rhizoma and their therapeutic potential for the treatment of Alzheimer’s disease

“…Next, the upregulated compounds were further screened from these overlapping metabolites. Afterward, the targets of those compounds were obtained by searching the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database and the Swiss Target Prediction database ( Song et al, 2021 ).…”